Last reviewed 2026-04-20 · How we verify

Accupril (QUINAPRIL)

Accupril (quinapril) is an Angiotensin Converting Enzyme Inhibitor (ACE inhibitor) developed by Pfizer Pharmaceuticals. It targets the angiotensin-converting enzyme to treat chronic heart failure and hypertensive disorders. Originally approved in 1991, Accupril is now off-patent with multiple generic manufacturers. The drug has a half-life of 25 hours and bioavailability of 60%. As an off-patent medication, it is widely available in the market.

At a glance

Approved indications

• Chronic heart failure
• Hypertensive disorder

Common side effects

• Headache
• Dizziness
• Coughing
• Fatigue
• Nausea and/or Vomiting
• Hypotension
• Dyspnea
• Diarrhea
• Chest Pain
• Abdominal Pain
• Back Pain
• Rash

Drug interactions

• spironolactone
• triamterene

Key clinical trials

• Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
• Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
• Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
• Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg (PHASE1)
• Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg (PHASE1)
• Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg (PHASE1)
• Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg (PHASE1)
• Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.